AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31548616 — intervention group
Group type: COMPARATOR
Intervention: Fully-automated BP measurements
Number of subjects: 172
Study 31548616 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated BP measurement
Number of subjects: 172
Study 31548616 — intervention group
Group type: COMPARATOR
Intervention: Fully-automated self-measurement
Number of subjects: 172
Study 29859224 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall Technique (HT)
Number of subjects: 142
Study 29859224 — intervention group
Group type: COMPARATOR
Intervention: Non‐Restorative Cavity Control (NRCC)
Number of subjects: 142
Study 29859224 — intervention group
Group type: COMPARATOR
Intervention: Conventional carious tissue removal and restoration (CR)
Number of subjects: 142
Study 28716003 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW (eccentric resistance exercise)
Number of subjects: 0
Study 28716003 — intervention group
Group type: COMPARATOR
Intervention: TRAD (traditional resistance exercise)
Number of subjects: 0
Study 28716003 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEW
Number of subjects: 0
Study 28716003 — intervention group
Group type: COMPARATOR
Intervention: TRAD
Number of subjects: 0
Study 26277295 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of intracoronary diltiazem
Number of subjects: 60
Study 26277295 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study 24151589 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES + Ex (neuromuscular electrical stimulation combined with exercises)
Number of subjects: 100
Study 24151589 — intervention group
Group type: COMPARATOR
Intervention: Ex (exercise program)
Number of subjects: 100
Study 20369218 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (Dru Yoga, 60-minute class once a week for six weeks)
Number of subjects: 48
Study 20369218 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention)
Number of subjects: 48
Study 18774746 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 1214
Study 18774746 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 1214
Study 16840514 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) intravenous infusion at 125 mg kg(‐1) h(‐1) for 15 min, then 25 mg kg(‐1) h(‐1) for 20 min prior to and throughout exercise
Number of subjects: 8
Study 16840514 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 8
Study 16840514 — intervention group
Group type: COMPARATOR
Intervention: Saline (CON)
Number of subjects: 8
Study 12790813 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 30
Study 12790813 — intervention group
Group type: COMPARATOR
Intervention: Control (Normal Saline)
Number of subjects: 30
Study 10959784 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage full-mouth disinfection with chlorhexidine (Fdis)
Number of subjects: 36
Study 10959784 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage full-mouth root planing without chlorhexidine (FRp)
Number of subjects: 36
Study 10959784 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment with quadrant root planing)
Number of subjects: 36
Study 8638837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 mg/h
Number of subjects: 20
Study 8638837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg/h
Number of subjects: 20
Study 8638837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (total and unbound plasma concentrations)
Number of subjects: 20
Study 8638837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (unbound clearance)
Number of subjects: 20
Study 1350610 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg four times a day)
Number of subjects: 132
Study 1350610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide (500 mg four times a day)
Number of subjects: 132
Study 1350610 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (2 gm daily) alone
Number of subjects: 132
Study 6087397 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 16
Study 6087397 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study 31402562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bev) in combination with sequential chemotherapy
Number of subjects: 132
Study 31402562 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 132
Study 31402562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bev)
Number of subjects: 132
Study 28971905 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐methylprednisolone 1 mg/kg/day
Number of subjects: 171
Study 28971905 — intervention group
Group type: COMPARATOR
Intervention: Observation arm
Number of subjects: 171
Study 26499860 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-based intervention program
Number of subjects: 427
Study 26499860 — intervention group
Group type: EXPERIMENTAL
Intervention: Islamic-based intervention program
Number of subjects: 427
Study 26499860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention group (Health + Islamic)
Number of subjects: 427
Study 26499860 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 427
Study 23640303 — intervention group
Group type: EXPERIMENTAL
Intervention: Group map-based program (intervention)
Number of subjects: 134
Study 23640303 — intervention group
Group type: COMPARATOR
Intervention: Group education on cholesterol and blood pressure (control)
Number of subjects: 134
Study 23640303 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 134
Study 21247455 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health workers trained in a cultural module
Number of subjects: 150
Study 21247455 — intervention group
Group type: COMPARATOR
Intervention: Mental health workers not trained in a cultural module
Number of subjects: 150
Study 19056744 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impedance leads
Number of subjects: 40
Study 19056744 — intervention group
Group type: COMPARATOR
Intervention: Standard impedance leads
Number of subjects: 40
Study 16567671 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 81
Study 12796664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises (PFE) with biofeedback and physical therapist guidance, performed before and after surgery, with home exercises twice daily after surgery.
Number of subjects: 38
Study 12796664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no formal PFE instructions), underwent surgery only.
Number of subjects: 38
Study 10843163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate treatment
Number of subjects: 9
Study 10843163 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 9
Study 8666626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented prosthesis
Number of subjects: 250
Study 8666626 — intervention group
Group type: COMPARATOR
Intervention: Non-cemented prosthesis
Number of subjects: 250
Study 8666626 — intervention group
Group type: EXPERIMENTAL
Intervention: Venography (in patients with isolated distal thrombi)
Number of subjects: 250
Study 1450186 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (30 to 90 mg)
Number of subjects: 242
Study 1450186 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (120 to 240 mg)
Number of subjects: 242
Study 1450186 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (300 to 600 mg)
Number of subjects: 242
Study 1450186 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (15 to 45 mg)
Number of subjects: 242
Study 6428380 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative percutaneous biliary drainage (PBD)
Number of subjects: 50
Study 6428380 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous transhepatic cholangiography (PTHC) followed immediately by operation (Control)
Number of subjects: 50
Study 29260507 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab in combination with bortezomib and dexamethasone (DVd)
Number of subjects: 8
Study 27097939 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoacoustic emissions (OAE) measurements before surgery
Number of subjects: 39
Study 27097939 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoacoustic emissions (OAE) measurements during surgery
Number of subjects: 39
Study 27097939 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoacoustic emissions (OAE) measurements after surgery
Number of subjects: 39
Study 25204191 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxin granules combined with tirofiban
Number of subjects: 120
Study 25204191 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban alone
Number of subjects: 120
Study 22878383 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% gatifloxacin hydrochloride
Number of subjects: 513
Study 22878383 — intervention group
Group type: COMPARATOR
Intervention: 5% povidone‐iodine
Number of subjects: 513
Study 22878383 — intervention group
Group type: COMPARATOR
Intervention: 0.4% amikacin sulphate
Number of subjects: 513
Study 20976066 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO rs9939609 A allele
Number of subjects: 1550
Study 17822751 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing (by Hybrid Capture 2) alone at 2 RLU cut-off in age group 35-60
Number of subjects: 45307
Study 17822751 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing alone as screening test in age group 25-34
Number of subjects: 45307
Study 17822751 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding liquid-based cytology as screening test in age group 35-60
Number of subjects: 45307
Study 17822751 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV positive women triaged by cytology in age group 25-34
Number of subjects: 45307
Study 16201396 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based video support system (Visual Training System) during practical training
Number of subjects: 84
Study 16201396 — intervention group
Group type: COMPARATOR
Intervention: Control group received instruction in scaling and root planing instruments during a 7-hour seminar and 2 hours of manual practice
Number of subjects: 84
Study 12009297 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide Nm vaccine
Number of subjects: 157
Study 12009297 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 157
Study 10427132 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary telomerase activity before TUR
Number of subjects: 26
Study 10427132 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary telomerase activity after TUR
Number of subjects: 26
Study 7481633 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGE test
Number of subjects: 416
Study 7481633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CAGE test)
Number of subjects: 416
Study 2287557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of pentoxifylline and theophylline
Number of subjects: 9
Study 2287557 — intervention group
Group type: COMPARATOR
Intervention: Theophylline administration alone
Number of subjects: 9
Study 6992196 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide (nonionic contrast medium)
Number of subjects: 0
Study 6992196 — intervention group
Group type: COMPARATOR
Intervention: Methylglucamine iothalamate (ionic contrast medium)
Number of subjects: 0
Study 31825075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate beverage (CHO; 210 kcal; 0 g fat/56 g carbohydrates/0 g protein)
Number of subjects: 17
Study 31825075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate beverage (CHO)
Number of subjects: 17
Study 31229045 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-concentration tacrolimus and steroids
Number of subjects: 0
Study 31229045 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate, tacrolimus, and steroids
Number of subjects: 0
Study 26035033 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat plus diacerein
Number of subjects: 64
Study 26035033 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat alone
Number of subjects: 64
Study 25885664 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (Pre-exposure prophylaxis)
Number of subjects: 99009
Study 25885664 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV tests
Number of subjects: 99009
Study 25885664 — intervention group
Group type: EXPERIMENTAL
Intervention: Total visits with positive rapid test results
Number of subjects: 99009
Study 23688534 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteolin and quercetin dietary supplement (100 mg luteolin, 70 mg quercetin, 30 mg rutin per capsule, 1 capsule per 10 kg weight per day with food)
Number of subjects: 50
Study 23688534 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteolin and quercetin dietary supplement
Number of subjects: 50
Study 21268724 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus adefovir dipivoxil
Number of subjects: 90
Study 21268724 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus placebo
Number of subjects: 90
Study 21268724 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil alone
Number of subjects: 90
Study 21268724 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a plus adefovir dipivoxil or peginterferon alfa‐2a alone
Number of subjects: 90
Study 19265788 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium (HS) intake (200 mEq/24 h)
Number of subjects: 80
Study 19265788 — intervention group
Group type: COMPARATOR
Intervention: Low sodium (LS) intake (10 mEq/24 h)
Number of subjects: 80
Study 17393191 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 nm laser
Number of subjects: 70
Study 17393191 — intervention group
Group type: EXPERIMENTAL
Intervention: 780 nm laser
Number of subjects: 70
Study 17393191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 12496059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (part of nicotine replacement therapy)
Number of subjects: 304
Study 12496059 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine concentrations of anabasine and anatabine
Number of subjects: 304
Study 12496059 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported tobacco use
Number of subjects: 304
Study 10527226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.0 mg/kg
Number of subjects: 32
Study 10527226 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.15 mg/kg
Number of subjects: 32
Study 7726306 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (low dose: 0.5 mg/kg per day)
Number of subjects: 80
Study 7726306 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (medium dose: 1.5 mg/kg per day)
Number of subjects: 80
Study 7726306 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (high dose: 3.0 mg/kg per day)
Number of subjects: 80
Study 7726306 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (all doses)
Number of subjects: 80
Study 7726306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 7726306 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (high dose)
Number of subjects: 80
Study 2019075 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin perfusion pressure using an isotope technique
Number of subjects: 226
Study 2019075 — intervention group
Group type: COMPARATOR
Intervention: Doppler ankle pressure measurements
Number of subjects: 226
Study 6444379 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 percent benzoyl peroxide lotion
Number of subjects: 0
Study 6444379 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31588886 — intervention group
Group type: COMPARATOR
Intervention: ZnSO4 (n = 15)
Number of subjects: 44
Study 31588886 — intervention group
Group type: EXPERIMENTAL
Intervention: ZnAA (n = 14)
Number of subjects: 44
Study 31588886 — intervention group
Group type: COMPARATOR
Intervention: CON (n = 15)
Number of subjects: 44
Study 29388435 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 home visits with a health educator, tailored emails, and mailed incentives (4HV)
Number of subjects: 45
Study 29388435 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 home visits with a health educator, tailored emails, and mailed incentives (2HV)
Number of subjects: 45
Study 29388435 — intervention group
Group type: COMPARATOR
Intervention: General health advice through emails (control)
Number of subjects: 45
Study 28947449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Matters intervention (4-month occupational therapy intervention)
Number of subjects: 13
Study 25824586 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (vACV) 8 g/day
Number of subjects: 117
Study 25824586 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir (vGCV) 900 mg/day
Number of subjects: 117
Study 23429202 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatar therapy
Number of subjects: 0
Study 23429202 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 23429202 — intervention group
Group type: COMPARATOR
Intervention: Crossover control (TAU vs Avatar therapy)
Number of subjects: 0
Study 22015094 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μM ASA
Number of subjects: 26
Study 22015094 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no specific intervention mentioned)
Number of subjects: 26
Study 18444110 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreeableness
Number of subjects: 0
Study 18444110 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscientiousness
Number of subjects: 0
Study 18444110 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality facets
Number of subjects: 0
Study 18444110 — intervention group
Group type: COMPARATOR
Intervention: Social information processing and behavioral discounting variables
Number of subjects: 0
Study 17220051 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (rosiglitazone 8 mg)
Number of subjects: 28
Study 17220051 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (rosiglitazone 8 mg)
Number of subjects: 28
Study 12644428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% and lidocaine 2%
Number of subjects: 90
Study 12644428 — intervention group
Group type: COMPARATOR
Intervention: L-bupivacaine 0.75% and lidocaine 2%
Number of subjects: 90
Study 12644428 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 10335782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus postoperative radiotherapy
Number of subjects: 1375
Study 10335782 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 1375
Study 8529086 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and educational cardiac rehabilitation program, including 6 weekly group sessions and personalized behavior modification program.
Number of subjects: 86
Study 8529086 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 86
Study 2153728 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 32
Study 2153728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7008293 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antithymocyte globulin (ATG) therapy
Number of subjects: 90
Study 7008293 — intervention group
Group type: COMPARATOR
Intervention: Standard antirejection treatment (SAT)
Number of subjects: 90
Study 31773201 — intervention group
Group type: EXPERIMENTAL
Intervention: ISB with DEX (1 ml DEX + 8 ml 0.75% ropivacaine)
Number of subjects: 50
Study 31773201 — intervention group
Group type: COMPARATOR
Intervention: ISB alone (1 ml normal saline + 8 ml ropivacaine)
Number of subjects: 50
Study 31663769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (o‐CEE; n = 109)
Number of subjects: 362
Study 31663769 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β‐estradiol (t‐E2; n = 107)
Number of subjects: 362
Study 31663769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 146)
Number of subjects: 362
Study 30231542 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread
Number of subjects: 7
Study 30231542 — intervention group
Group type: COMPARATOR
Intervention: White rice
Number of subjects: 7
Study 26600287 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy for 10 weeks
Number of subjects: 212
Study 26600287 — intervention group
Group type: COMPARATOR
Intervention: Topical overnight application of lidocaine for 10 weeks
Number of subjects: 212
Study 26600287 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physiotherapy
Number of subjects: 212
Study 26600287 — intervention group
Group type: COMPARATOR
Intervention: Topical overnight application of lidocaine
Number of subjects: 212
Study 24470392 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea consumption
Number of subjects: 579
Study 24470392 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 579
Study 24470392 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 579
Study 22172440 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 600
Study 22172440 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 600
Study 20855414 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention (n = 65)
Number of subjects: 130
Study 20855414 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 65)
Number of subjects: 130
Study 17372057 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colectomy
Number of subjects: 1536
Study 17372057 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 1536
Study 16295212 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.3 mg
Number of subjects: 13
Study 16295212 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3.0 mg
Number of subjects: 13
Study 16295212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13